Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial
Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
SAGE Publishing
2016-03-01
|
| 叢編: | Therapeutic Advances in Gastroenterology |
| 在線閱讀: | https://doi.org/10.1177/1756283X15621232 |